Medical Research Council Unit, The Gambia.
PLoS Med. 2011 Oct;8(10):e1001107. doi: 10.1371/journal.pmed.1001107. Epub 2011 Oct 18.
Introduction of pneumococcal conjugate vaccines (PCVs) of limited valency is justified in Africa by the high burden of pneumococcal disease. Long-term beneficial effects of PCVs may be countered by serotype replacement. We aimed to determine the impact of PCV-7 vaccination on pneumococcal carriage in rural Gambia.
A cluster-randomized (by village) trial of the impact of PCV-7 on pneumococcal nasopharyngeal carriage was conducted in 21 Gambian villages between December 2003 to June 2008 (5,441 inhabitants in 2006). Analysis was complemented with data obtained before vaccination. Because efficacy of PCV-9 in young Gambian children had been shown, it was considered unethical not to give PCV-7 to young children in all of the study villages. PCV-7 was given to children below 30 mo of age and to those born during the trial in all study villages. Villages were randomized (older children and adults) to receive one dose of PCV-7 (11 vaccinated villages) or meningococcal serogroup C conjugate vaccine (10 control villages). Cross-sectional surveys (CSSs) to collect nasopharyngeal swabs were conducted before vaccination (2,094 samples in the baseline CSS), and 4-6, 12, and 22 mo after vaccination (1,168, 1,210, and 446 samples in CSS-1, -2, and -3, respectively). A time trend analysis showed a marked fall in the prevalence of vaccine-type pneumococcal carriage in all age groups following vaccination (from 23.7% and 26.8% in the baseline CSS to 7.1% and 8.5% in CSS-1, in vaccinated and control villages, respectively). The prevalence of vaccine-type pneumococcal carriage was lower in vaccinated than in control villages among older children (5 y to <15 y of age) and adults (≥15 y of age) at CSS-2 (odds ratio [OR] = 0.15 [95% CI 0.04-0.57] and OR = 0.32 [95% CI 0.10-0.98], respectively) and at CSS-3 (OR = 0.37 [95% CI 0.15-0.90] for older children, and 0% versus 7.6% for adults in vaccinated and control villages, respectively). Differences in the prevalence of non-vaccine-type pneumococcal carriage between vaccinated and control villages were small.
Vaccination of Gambian children reduced vaccine-type pneumococcal carriage across all age groups, indicating a "herd effect" in non-vaccinated older children and adults. No significant serotype replacement was detected. Please see later in the article for the Editors' Summary.
在非洲,由于肺炎球菌疾病负担沉重,引入价效有限的肺炎球菌结合疫苗(PCV)是合理的。PCV 的长期有益效果可能会因血清型替代而受到影响。我们旨在确定 PCV-7 疫苗接种对冈比亚农村地区肺炎球菌定植的影响。
2003 年 12 月至 2008 年 6 月期间,在冈比亚的 21 个村庄中,进行了一项 PCV-7 对肺炎球菌鼻咽携带影响的群组随机(按村庄)试验(2006 年共有 5441 名居民)。分析中还补充了接种前获得的数据。由于已证明 PCV-9 在冈比亚幼儿中的疗效,因此不给所有研究村庄的幼儿接种 PCV-7 被认为是不道德的。PCV-7 接种给 30 个月以下的儿童和所有研究村庄在试验期间出生的儿童。根据年龄(较大的儿童和成年人)将村庄随机分组(接受一剂 PCV-7(11 个接种村庄)或脑膜炎球菌 C 群结合疫苗(10 个对照村庄))。在接种前(基线 CSS 中 2094 个样本)以及接种后 4-6、12 和 22 个月(CSS-1、-2 和-3 中分别有 1168、1210 和 446 个样本)进行了横断面调查(CSS)以收集鼻咽拭子。接种后,所有年龄组的疫苗型肺炎球菌定植率均明显下降(接种和对照组在基线 CSS 中的疫苗型肺炎球菌携带率分别为 23.7%和 26.8%,而在 CSS-1 中分别为 7.1%和 8.5%)。在 CSS-2(比值比 [OR]为 0.15[95%CI 0.04-0.57]和 OR 为 0.32[95%CI 0.10-0.98])和 CSS-3(OR 为 0.37[95%CI 0.15-0.90]对于较大的儿童,以及接种和对照组在 CSS-3 中分别为 0%和 7.6%)中,疫苗型肺炎球菌携带率在接种疫苗的较大儿童和成年人中低于对照组。接种和对照组之间非疫苗型肺炎球菌定植率的差异较小。
冈比亚儿童的疫苗接种降低了所有年龄组的疫苗型肺炎球菌定植率,表明非接种的较大儿童和成年人中存在“群体效应”。未发现明显的血清型替代。请稍后在文章中查看编辑摘要。